European SPC Waiver for Export and Stockpiling of Generics and Biosimilars

27-03-2019

On 14 February 2019, the Committee of the Permanent Representatives of the Governments of the Member States (Coreper) endorsed a draft regulation which introduces an exception to the protection granted to a medicinal product by a supplementary protection certificate (SPC) for export purposes and/or stockpiling. Next step is submission to the European Parliament and Council for adoption.

Please read more on this topic in our newsletter.

NautaDutilh assisted biotech company Arvelle Therapeutics alongside Sidley Austin on its acquisition by Italian Biotech Angelini Pharma. The deal is the largest acquisition for the 100-year old Angelini. Quoting both its CEO and executive vice president: “It’s the most important investment in the history of our Group”.

Deal or case news

NautaDutilh assisted Arvelle Therapeutics on its acquisition by Angelini Pharma

NautaDutilh assisted biotech company Arvelle Therapeutics alongside Sidley Austin on its acquisition by Italian Biotech Angelini Pharma. The deal is the largest acquisition for the 100-year old Ang...

On 14 August 2020, CureVac N.V. announced the successful pricing of its underwritten IPO for up to USD 245 million in new common shares. The IPO will close concurrently with a USD 118 million private placement and follows a recent USD 640 million private financing round, for total equity investments exceeding USD 1 billion. NautaDutilh has acted as Dutch counsel to CureVac on the private financing round, the IPO and the concurrent private placement, alongside Davis Polk & Wardwell (US counsel to CureVac) an

Deal or case news

NautaDutilh assists CureVac on the private financing round, IPO and private placement

On 14 August 2020, CureVac NV launched a successful IPO on the Nasdag Global Market, raising USD 213 million. The company raised a further USD 118 million in a private placement and recently comple...

How can we help you?